Matthew J. Ellis

Baylor College of Medicine, Houston, TX 
"Matthew Ellis"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Lei JT, Jaehnig EJ, Smith H, et al. (2023) The Breast Cancer Proteome and Precision Oncology. Cold Spring Harbor Perspectives in Medicine
Gou X, Kim BJ, Anurag M, et al. (2023) Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer. Cancer Research
Anurag M, Jaehnig EJ, Krug K, et al. (2022) Proteogenomic markers of chemotherapy resistance and response in triple negative breast cancer. Cancer Discovery
Kalra R, Chen CH, Wang J, et al. (2022) Poziotinib inhibits HER2 mutant-driven therapeutic resistance and multi-organ metastasis in breast cancer. Cancer Research
Eteleeb AM, Thunuguntla PK, Gelev KZ, et al. (2022) LINC00355 regulates p27 expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. Npj Breast Cancer. 8: 49
Ademuyiwa FO, Chen I, Luo J, et al. (2021) Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Research and Treatment
Punturi NB, Seker S, Devarakonda V, et al. (2021) Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. Nature Communications. 12: 2940
Watt AC, Cejas P, DeCristo MJ, et al. (2021) CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer. 2: 34-48
Wang X, Veeraraghavan J, Liu CC, et al. (2021) Therapeutic targeting of nemo-like kinase in primary and acquired endocrine-resistant breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Bowling EA, Wang JH, Gong F, et al. (2021) Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell
See more...